Prelude Capital Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Prelude Capital Management’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-23,649	Closed	-$1.06M	–	1937
2017 Q3	$1.06M	Buy	23,649 +15,071	+176%	+$514K	0.1%	231
2017 Q2	$256K	Sell	8,578 -1,922	-18%	-$47.4K	0.02%	506
2017 Q1	$233K	Buy	10,500 +5,456	+108%	+$117K	0.02%	518
2016 Q4	$95K	Buy	5,044 +5,024	+25,120%	+$123K	0.01%	857
2016 Q3	$1K	Sell	20 -480	-96%	-$14.9K	﹤0.01%	1555
2016 Q2	$19K	Buy	500 +200	+67%	+$8.3K	﹤0.01%	1299
2016 Q1	$11K	Buy	+300	New	+$10.5K	﹤0.01%	1168
2015 Q3	–	Sell	-500	Closed	-$27K	–	1974
2015 Q2	$27K	Buy	+500	New	+$26.5K	﹤0.01%	1303

Other funds holding JUNO

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Prelude Capital Management's JUNO Position: Q4 2017 in Review

Prelude Capital Management sold out of Juno Therapeutics, Inc. (JUNO) in Q4 2017, closing a stake of 23,649 shares — an estimated $1.06M sold.

Prelude Capital Management first reported a position in JUNO in Q2 2015 and held it in 8 quarters. The position peaked at $1.06M in Q3 2017. 237 funds tracked by Wall St. Rank hold JUNO as of Q4 2017.

Prelude Capital Management reported no remaining Juno Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
Prelude Capital Management sold 23,649 Juno Therapeutics, Inc. shares in Q4 2017, an estimated $1.06M.
Prelude Capital Management first reported a position in Juno Therapeutics, Inc. in Q2 2015 and held it in 8 quarters.
Prelude Capital Management's Juno Therapeutics, Inc. position peaked at $1.06M in Q3 2017.
237 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2017.

Based on Prelude Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.